Recombinant Human Endocrine Gland-Derived Vascular Endothelial Growth Factor (EG-hVEGF) is selectively expressed in steroidogenic glands and promotes the growth of endocrine gland endothelium. The identification of tissue-selective angiogenic factors raises the possibility that other secreted molecules in this class exist. Consistent with such an expression pattern, the human EG-VEGF gene promoter has a potential binding site for steroidogenic factor-1, a pivotal element for steroidogenic-specific transcription. In the human ovary, the expression of EG-VEGF is temporally and spatially complementary to the expression of VEGF-A, both in the follicular and in the luteal phase, suggesting complementary and coordinated roles of these molecules in ovarian angiogenesis. Also, EG-VEGF expression correlates with vascularity in the polycystic ovary syndrome, a leading cause of infertility.
Note: This EG-hVEGF is fully bio-active as determined by the dose-dependent stimulation of the proliferation of human umbilical vein endothelial cells (HUVEC) using a concentration range of 1.0-5.0 ng/ml.
|VEGF 121, CF||PR15029CF|
|VEGF 162, CF||PR15030CF|
|VEGF 165, CF||PR15031CF|
|VEGF/PIGF Heterodimer, CF||PR15032CF|
|VEGF 164, CF||PR15034CF|
|VEGF 164, CF||PR15035CF|